Chen X - Search Results

1

Clinical perspective of afatinib in non-small cell lung cancer.

Chen X, Zhu Q, Zhu L, Pei D, Liu Y, Yin Y, Schuler M, Shu Y. Chen X, et al. Lung Cancer. 2013 Aug;81(2):155-61. doi: 10.1016/j.lungcan.2013.02.021. Epub 2013 May 10. Lung Cancer. 2013. PMID: 23664448 Review.

2

Icotinib is an active treatment of non-small-cell lung cancer: a retrospective study.

Chen X, Zhu Q, Liu Y, Liu P, Yin Y, Guo R, Lu K, Gu Y, Liu L, Wang J, Wang Z, Røe OD, Shu Y, Zhu L. Chen X, et al. PLoS One. 2014 May 16;9(5):e95897. doi: 10.1371/journal.pone.0095897. eCollection 2014. PLoS One. 2014. PMID: 24836053 Free PMC article.

3

CD137 ligand-mediated reverse signaling inhibits proliferation and induces apoptosis in non-small cell lung cancer.

Qian Y, Pei D, Cheng T, Wu C, Pu X, Chen X, Liu Y, Shen H, Zhang W, Shu Y. Qian Y, et al. Among authors: chen x. Med Oncol. 2015 Mar;32(3):44. doi: 10.1007/s12032-015-0499-9. Epub 2015 Jan 29. Med Oncol. 2015. PMID: 25631633

4

Effect of gefitinib challenge to initial treatment with non-small cell lung cancer.

Chen X, Li W, Hu X, Geng Y, Wang R, Yin Y, Shu Y. Chen X, et al. Biomed Pharmacother. 2011 Dec;65(8):542-6. doi: 10.1016/j.biopha.2011.04.017. Epub 2011 Jun 12. Biomed Pharmacother. 2011. PMID: 21840160 Clinical Trial.

5

Gefitinib or erlotinib as maintenance therapy in patients with advanced stage non-small cell lung cancer: a systematic review.

Chen X, Liu Y, Røe OD, Qian Y, Guo R, Zhu L, Yin Y, Shu Y. Chen X, et al. PLoS One. 2013;8(3):e59314. doi: 10.1371/journal.pone.0059314. Epub 2013 Mar 21. PLoS One. 2013. PMID: 23555654 Free PMC article. Review.

6

TGF-β1 induces erlotinib resistance in non-small cell lung cancer by down-regulating PTEN.

Shen H, Guan D, Shen J, Wang M, Chen X, Xu T, Liu L, Shu Y. Shen H, et al. Among authors: chen x. Biomed Pharmacother. 2016 Feb;77:1-6. doi: 10.1016/j.biopha.2015.10.018. Epub 2015 Nov 28. Biomed Pharmacother. 2016. PMID: 26796257

7

Prediction of non-small cell lung cancer metastasis-associated microRNAs using bioinformatics.

Wang R, Chen XF, Shu YQ. Wang R, et al. Am J Cancer Res. 2014 Dec 15;5(1):32-51. eCollection 2015. Am J Cancer Res. 2014. PMID: 25628919 Free PMC article.

8

The ERCC1 C118T polymorphism predicts clinical outcomes of colorectal cancer patients receiving oxaliplatin-based chemotherapy: a meta-analysis based on 22 studies.

Qian YY, Liu XY, Wu Q, Song X, Chen XF, Liu YQ, Pei D, Shen LZ, Shu YQ. Qian YY, et al. Among authors: chen xf. Asian Pac J Cancer Prev. 2014;15(19):8383-90. doi: 10.7314/apjcp.2014.15.19.8383. Asian Pac J Cancer Prev. 2014. PMID: 25339033 Free article.

9

The XPD Lys751Gln polymorphism has predictive value in colorectal cancer patients receiving oxaliplatin-based chemotherapy: a systemic review and meta-analysis.

Qian YY, Liu XY, Pei D, Xu JL, Shen H, Chen XF, Liu YQ, Shen LZ, Shu YQ. Qian YY, et al. Asian Pac J Cancer Prev. 2014;15(22):9699-706. doi: 10.7314/apjcp.2014.15.22.9699. Asian Pac J Cancer Prev. 2014. PMID: 25520091 Free article. Review.

10

ObRb downregulation increases breast cancer cell sensitivity to tamoxifen.

Qian Y, Shi D, Qiu J, Zhu F, Qian J, He S, Shu Y, Yin Y, Chen X. Qian Y, et al. Among authors: chen x. Tumour Biol. 2015 Sep;36(9):6813-21. doi: 10.1007/s13277-015-3375-5. Epub 2015 Apr 7. Tumour Biol. 2015. PMID: 25846733

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

115,619 results

Search Page

Filters